Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

DiNardo

Showing results (1061-1070 of 1,482) with videos related to

Pageof 149
Sort By:
Blood|June 17, 2022
Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trialStéphane de Botton, Pau Montesinos, Andre C Schuh, et al.
Blood Cancer Journal|April 17, 2025
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patientsChristophe Willekens, Alexandre Bazinet, Samy Chraibi, et al.
Cancer|April 1, 2021
Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemiaCaitlin R Rausch, Courtney D DiNardo, Abhishek Maiti, et al.
Blood Cancer Journal|May 21, 2021
Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cellsWarren Fiskus, Christopher P Mill, Behnam Nabet, et al.
British Journal of Haematology|August 2, 2021
Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndromeKelly S Chien, Kunhwa Kim, Graciela M Nogueras-Gonzalez, et al.
Leukemia|March 12, 2026
Immunophenotypic changes following menin inhibition in acute myeloid leukemiaSanam Loghavi, Aziz Farhat, Trevor J Jamison, et al.
Journal of Hematology & Oncology|July 8, 2023
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agentsNicholas J Short, Muharrem Muftuoglu, Faustine Ong, et al.
Blood|November 5, 2025
Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapySven Turkalj, Felix A Radtke, Bilyana Stoilova, et al.
Nature Communications|November 26, 2021
Hematopoiesis under telomere attrition at the single-cell resolutionNatthakan Thongon, Feiyang Ma, Andrea Santoni, et al.
Nature Communications|May 11, 2021
Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemiaFeng Wang, Kiyomi Morita, Courtney D DiNardo, et al.
Pageof 149

Showing results (1061-1070 of 1,482) with videos related to

Sort By:
Pageof 149
Blood|June 17, 2022
Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trialStéphane de Botton, Pau Montesinos, Andre C Schuh, et al.
Blood Cancer Journal|April 17, 2025
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patientsChristophe Willekens, Alexandre Bazinet, Samy Chraibi, et al.
Cancer|April 1, 2021
Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemiaCaitlin R Rausch, Courtney D DiNardo, Abhishek Maiti, et al.
Blood Cancer Journal|May 21, 2021
Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cellsWarren Fiskus, Christopher P Mill, Behnam Nabet, et al.
British Journal of Haematology|August 2, 2021
Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndromeKelly S Chien, Kunhwa Kim, Graciela M Nogueras-Gonzalez, et al.
Leukemia|March 12, 2026
Immunophenotypic changes following menin inhibition in acute myeloid leukemiaSanam Loghavi, Aziz Farhat, Trevor J Jamison, et al.
Journal of Hematology & Oncology|July 8, 2023
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agentsNicholas J Short, Muharrem Muftuoglu, Faustine Ong, et al.
Blood|November 5, 2025
Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapySven Turkalj, Felix A Radtke, Bilyana Stoilova, et al.
Nature Communications|November 26, 2021
Hematopoiesis under telomere attrition at the single-cell resolutionNatthakan Thongon, Feiyang Ma, Andrea Santoni, et al.
Nature Communications|May 11, 2021
Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemiaFeng Wang, Kiyomi Morita, Courtney D DiNardo, et al.
Pageof 149